| Dr Claude Shreve Burton Iii, MD | |
|
40 Duke Medicine Cir, Durham, NC 27710 | |
| (919) 681-5442 | |
| (919) 681-7991 |
| Full Name | Dr Claude Shreve Burton Iii |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 45 Years |
| Location | 40 Duke Medicine Cir, Durham, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295761021 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 25694 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Duke University Hospital | Durham, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Duke Health Integrated Practice Inc | 8325412737 | 2551 |
News Archive
In an examination of risk factors associated with suicide in current and former military personnel observed 2001 and 2008, male sex and mental disorders were independently associated with suicide risk but not military-specific variables, findings that do not support an association between deployment or combat with suicide, according to a study in the August 7 issue of JAMA, a theme issue on violence/human rights.
A new study published in Developmental Cell investigates S-acylation of the SARS-CoV-2 S protein.
A luminescent fluid made up of nanoparticles that allows more accurate observation of different areas of the organism has been developed by a research team from the Colloidal Materials group of the Institute of Materials Science of Seville (a CSIC-University of Seville joint centre) in collaboration with the Institute of Materials Science of Aragon, the Andalusian Centre of Medicine and Biotechnology (BIONAND) and the Spanish National Accelerator Centre (CNA).
Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that Astellas will undertake a single confirmatory additional Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection for rapid conversion of atrial fibrillation to sinus rhythm. The trial, to be called ACT 5, is expected to begin enrolling patients by the end of 2009, with completion expected in the first half of 2011.
On the heels of the Federal Drug Administration's (FDA) second public workshop to explore the public health considerations associated with e-cigarettes, nonprofit research organization RTI International released a new research paper "Exhaled Electronic Cigarette Emissions: What's Your Secondhand Exposure?," which explores the composition of e-cigarette vapor and the potential health impacts of secondhand exposure.
› Verified 2 days ago
| Entity Name | Private Diagnostic Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457389033 PECOS PAC ID: 1355254368 Enrollment ID: O20031204000577 |
News Archive
In an examination of risk factors associated with suicide in current and former military personnel observed 2001 and 2008, male sex and mental disorders were independently associated with suicide risk but not military-specific variables, findings that do not support an association between deployment or combat with suicide, according to a study in the August 7 issue of JAMA, a theme issue on violence/human rights.
A new study published in Developmental Cell investigates S-acylation of the SARS-CoV-2 S protein.
A luminescent fluid made up of nanoparticles that allows more accurate observation of different areas of the organism has been developed by a research team from the Colloidal Materials group of the Institute of Materials Science of Seville (a CSIC-University of Seville joint centre) in collaboration with the Institute of Materials Science of Aragon, the Andalusian Centre of Medicine and Biotechnology (BIONAND) and the Spanish National Accelerator Centre (CNA).
Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that Astellas will undertake a single confirmatory additional Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection for rapid conversion of atrial fibrillation to sinus rhythm. The trial, to be called ACT 5, is expected to begin enrolling patients by the end of 2009, with completion expected in the first half of 2011.
On the heels of the Federal Drug Administration's (FDA) second public workshop to explore the public health considerations associated with e-cigarettes, nonprofit research organization RTI International released a new research paper "Exhaled Electronic Cigarette Emissions: What's Your Secondhand Exposure?," which explores the composition of e-cigarette vapor and the potential health impacts of secondhand exposure.
› Verified 2 days ago
| Entity Name | Duke Health Integrated Practice Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205553369 PECOS PAC ID: 8325412737 Enrollment ID: O20230327002247 |
News Archive
In an examination of risk factors associated with suicide in current and former military personnel observed 2001 and 2008, male sex and mental disorders were independently associated with suicide risk but not military-specific variables, findings that do not support an association between deployment or combat with suicide, according to a study in the August 7 issue of JAMA, a theme issue on violence/human rights.
A new study published in Developmental Cell investigates S-acylation of the SARS-CoV-2 S protein.
A luminescent fluid made up of nanoparticles that allows more accurate observation of different areas of the organism has been developed by a research team from the Colloidal Materials group of the Institute of Materials Science of Seville (a CSIC-University of Seville joint centre) in collaboration with the Institute of Materials Science of Aragon, the Andalusian Centre of Medicine and Biotechnology (BIONAND) and the Spanish National Accelerator Centre (CNA).
Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that Astellas will undertake a single confirmatory additional Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection for rapid conversion of atrial fibrillation to sinus rhythm. The trial, to be called ACT 5, is expected to begin enrolling patients by the end of 2009, with completion expected in the first half of 2011.
On the heels of the Federal Drug Administration's (FDA) second public workshop to explore the public health considerations associated with e-cigarettes, nonprofit research organization RTI International released a new research paper "Exhaled Electronic Cigarette Emissions: What's Your Secondhand Exposure?," which explores the composition of e-cigarette vapor and the potential health impacts of secondhand exposure.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Claude Shreve Burton Iii, MD 5213 S Alston Ave, Durham, NC 27713-4430 Ph: (919) 684-8111 | Dr Claude Shreve Burton Iii, MD 40 Duke Medicine Cir, Durham, NC 27710 Ph: (919) 681-5442 |
News Archive
In an examination of risk factors associated with suicide in current and former military personnel observed 2001 and 2008, male sex and mental disorders were independently associated with suicide risk but not military-specific variables, findings that do not support an association between deployment or combat with suicide, according to a study in the August 7 issue of JAMA, a theme issue on violence/human rights.
A new study published in Developmental Cell investigates S-acylation of the SARS-CoV-2 S protein.
A luminescent fluid made up of nanoparticles that allows more accurate observation of different areas of the organism has been developed by a research team from the Colloidal Materials group of the Institute of Materials Science of Seville (a CSIC-University of Seville joint centre) in collaboration with the Institute of Materials Science of Aragon, the Andalusian Centre of Medicine and Biotechnology (BIONAND) and the Spanish National Accelerator Centre (CNA).
Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that Astellas will undertake a single confirmatory additional Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection for rapid conversion of atrial fibrillation to sinus rhythm. The trial, to be called ACT 5, is expected to begin enrolling patients by the end of 2009, with completion expected in the first half of 2011.
On the heels of the Federal Drug Administration's (FDA) second public workshop to explore the public health considerations associated with e-cigarettes, nonprofit research organization RTI International released a new research paper "Exhaled Electronic Cigarette Emissions: What's Your Secondhand Exposure?," which explores the composition of e-cigarette vapor and the potential health impacts of secondhand exposure.
› Verified 2 days ago
John F Carr, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 4012 Colville Rd, Durham, NC 27707 Phone: 919-489-1826 | |
Dr. John Carroll Murray, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: Box 2907 Div Derm Duke Univ Med Center, Durham, NC 27710 Phone: 919-684-2393 Fax: 919-684-6505 | |
Brooke A Jackson, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 245 E Nc Highway 54, Suite 202, Durham, NC 27713 Phone: 919-294-9440 Fax: 919-237-3899 | |
Dr. Michelle Bernadette Pavlis, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5324 Mcfarland Rd, Suite 210, Durham, NC 27707 Phone: 919-684-8111 | |
Dr. Sabrina Michelle Shearer, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5324 Mcfarland Rd, Durham, NC 27707 Phone: 919-401-3376 Fax: 919-401-0378 | |
Dr. Lawrence Etter, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3008 Pickett Rd, Durham, NC 27705 Phone: 919-286-7903 Fax: 919-286-7151 | |
Elizabeth L. West, P.A. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2100 Erwin Rd, Durham, NC 27710 Phone: 919-684-8111 |